ESC Premium Access

Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy


About the speaker

Professor Matthew Roe

Duke Clinical Research Institute, Durham (United States of America)
0 follower

4 more presentations in this session

Association of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors with cardiovascular events stratified by renal function: a network meta-analysis

Speaker: Mr A. Roddick (Oxford, GB)


Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial

Speaker: Doctor T. Vanassche (Leuven, BE)


Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials

Speaker: Miss O. Ghosh-Swaby (London, CA)


Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment

Speaker: Doctor R. Diaz (Rosario, AR)


Access the full session

Progress in secondary prevention - New treatments

Speakers: Professor M. Roe, Mr A. Roddick, Doctor T. Vanassche, Miss O. Ghosh-Swaby, Doctor R. Diaz

About the event



31 August - 4 September 2019

Sessions Presentations

Related content

ESC Premium Access

Arrhythmic mitral valve prolapse and mitral annular disjunction.

27 August 2021

ESC Premium Access

A case of diving into MINOCA.

27 August 2021

ESC Premium Access

Acute aortic syndrome in young population. A contemporary approach.

27 August 2021

This platform is supported by

logo Novo Nordisk